NCT06282965View on ClinicalTrials.gov

Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Traumatic Brain Injury
Interventions
DRUG

Angiotensin (1-7)

The drug will be dissolved in 0.9% USP/NF grade sterile for injection saline (NaCl) and prepared in a concentration that aligns with the participant's weight.

DRUG

Sterile saline

Sterile solution of 0.9% NaCl in water.

Trial Locations (1)

85724

RECRUITING

University of Arizona, Tucson

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of Arizona

OTHER